A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML) (2022)
Attributed to:
University of Oxford – Confidence in Concept 2019
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Type: Conference/Paper/Proceeding/Abstract
Volume: 22
Parent Publication: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
ISSN: 2152-2650